FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223569935> ?p ?o ?g. }

• W4223569935 endingPage "861" @default.
• W4223569935 startingPage "851" @default.
• W4223569935 abstract "Background: Randomized controlled trials established the cardiac protection of sodium–glucose cotransporter-2 (SGLT2) inhibitors among adults with type 2 diabetes. New evidence suggests that these results could extend to people without diabetes. Purpose: To evaluate the effect of SGLT2 inhibitors in patients with heart failure, regardless of the presence of type 2 diabetes. Data Sources: PubMed, Web of Science, Cochrane Library, and Embase (OVID interface). Study Selection: Eligible trials randomly assigned adults with heart failure to SGLT2 inhibitors or control. Data Extraction: Time-to-event individual patient data were reconstructed from published Kaplan–Meier plots; time-varying risk ratios (RRs) were calculated in half-, 1-, and 2-year time frames; and anticipated absolute benefits were calculated using simple models applying relative effects to baseline risks. Data Synthesis: Sodium–glucose cotransporter-2 inhibitors reduce hospitalization for heart failure by 37% (95% CI, 25% to 47%) at 6 months, 32% (CI, 20% to 42%) at 1 year, and 26% (CI, 10% to 40%) at 2 years (all high certainty) and reduce cardiovascular death by 14% (CI, 1% to 25%) at 1 year (high certainty). Nevertheless, low-certainty evidence did not indicate protection against all-cause death, kidney disease progression, or kidney failure. Anticipated absolute benefits are greater for patients treated in the first year and for those with poorer prognoses, such as those newly diagnosed with heart failure in the hospital. In addition, SGLT2 inhibitors doubled the risk for genital infections (RR, 2.69 [CI, 1.61 to 4.52]; high certainty). Limitation: Covariates were unavailable in meta-analyses with reconstructed individual patient data. Conclusion: Among people with heart failure, SGLT2 inhibitors reduce hospitalizations for heart failure regardless of the presence of diabetes; absolute benefits are most pronounced in first-year treatment and vary with prognostic factors. Clinicians should note the increased risk for genital infection in patients receiving SGLT2 inhibitors. Primary Funding Source: 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University. (PROSPERO: CRD42021255544)" @default.
• W4223569935 created "2022-04-15" @default.
• W4223569935 creator A5002547008 @default.
• W4223569935 creator A5017952355 @default.
• W4223569935 creator A5020341898 @default.
• W4223569935 creator A5025818509 @default.
• W4223569935 creator A5028666900 @default.
• W4223569935 creator A5031717153 @default.
• W4223569935 creator A5066253638 @default.
• W4223569935 creator A5069028657 @default.
• W4223569935 creator A5082089345 @default.
• W4223569935 creator A5085639572 @default.
• W4223569935 creator A5087745821 @default.
• W4223569935 creator A5090201932 @default.
• W4223569935 creator A5091607881 @default.
• W4223569935 date "2022-06-01" @default.
• W4223569935 modified "2023-09-29" @default.
• W4223569935 title "Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure" @default.
• W4223569935 cites W2047586716 @default.
• W4223569935 cites W2083650930 @default.
• W4223569935 cites W2126617656 @default.
• W4223569935 cites W2135369095 @default.
• W4223569935 cites W2146264128 @default.
• W4223569935 cites W2165010366 @default.
• W4223569935 cites W2492672367 @default.
• W4223569935 cites W2619772777 @default.
• W4223569935 cites W2626446274 @default.
• W4223569935 cites W2883756867 @default.
• W4223569935 cites W2885675882 @default.
• W4223569935 cites W2899764361 @default.
• W4223569935 cites W2900413769 @default.
• W4223569935 cites W2912654919 @default.
• W4223569935 cites W2912857009 @default.
• W4223569935 cites W2939222610 @default.
• W4223569935 cites W2964686707 @default.
• W4223569935 cites W2970684805 @default.
• W4223569935 cites W2972004025 @default.
• W4223569935 cites W2974260792 @default.
• W4223569935 cites W3001477424 @default.
• W4223569935 cites W3015179476 @default.
• W4223569935 cites W3018301168 @default.
• W4223569935 cites W3021074130 @default.
• W4223569935 cites W3036816724 @default.
• W4223569935 cites W3047950129 @default.
• W4223569935 cites W3081830235 @default.
• W4223569935 cites W3081921599 @default.
• W4223569935 cites W3093992036 @default.
• W4223569935 cites W3098234982 @default.
• W4223569935 cites W3099711662 @default.
• W4223569935 cites W3100542962 @default.
• W4223569935 cites W3101259738 @default.
• W4223569935 cites W3102766101 @default.
• W4223569935 cites W3112797339 @default.
• W4223569935 cites W3118615836 @default.
• W4223569935 cites W3118652086 @default.
• W4223569935 cites W3120821309 @default.
• W4223569935 cites W3133124837 @default.
• W4223569935 cites W3152804121 @default.
• W4223569935 cites W3163431844 @default.
• W4223569935 cites W3163923489 @default.
• W4223569935 cites W3180364105 @default.
• W4223569935 cites W3185786433 @default.
• W4223569935 cites W3193297191 @default.
• W4223569935 cites W3193598686 @default.
• W4223569935 cites W3201648180 @default.
• W4223569935 cites W4205497306 @default.
• W4223569935 cites W82015992 @default.
• W4223569935 doi "https://doi.org/10.7326/m21-4284" @default.
• W4223569935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35404670" @default.
• W4223569935 hasPublicationYear "2022" @default.
• W4223569935 type Work @default.
• W4223569935 citedByCount "19" @default.
• W4223569935 countsByYear W42235699352022 @default.
• W4223569935 countsByYear W42235699352023 @default.
• W4223569935 crossrefType "journal-article" @default.
• W4223569935 hasAuthorship W4223569935A5002547008 @default.
• W4223569935 hasAuthorship W4223569935A5017952355 @default.
• W4223569935 hasAuthorship W4223569935A5020341898 @default.
• W4223569935 hasAuthorship W4223569935A5025818509 @default.
• W4223569935 hasAuthorship W4223569935A5028666900 @default.
• W4223569935 hasAuthorship W4223569935A5031717153 @default.
• W4223569935 hasAuthorship W4223569935A5066253638 @default.
• W4223569935 hasAuthorship W4223569935A5069028657 @default.
• W4223569935 hasAuthorship W4223569935A5082089345 @default.
• W4223569935 hasAuthorship W4223569935A5085639572 @default.
• W4223569935 hasAuthorship W4223569935A5087745821 @default.
• W4223569935 hasAuthorship W4223569935A5090201932 @default.
• W4223569935 hasAuthorship W4223569935A5091607881 @default.
• W4223569935 hasConcept C126322002 @default.
• W4223569935 hasConcept C134018914 @default.
• W4223569935 hasConcept C164705383 @default.
• W4223569935 hasConcept C168563851 @default.
• W4223569935 hasConcept C177713679 @default.
• W4223569935 hasConcept C2776478404 @default.
• W4223569935 hasConcept C2777180221 @default.
• W4223569935 hasConcept C2777422806 @default.
• W4223569935 hasConcept C2778198053 @default.
• W4223569935 hasConcept C44249647 @default.

• next